Skip to main content
Premium Trial:

Request an Annual Quote

AlgoNomics, Genmab Collaborate on Antibody Research

NEW YORK (GenomeWeb News) – Belgium’s AlgoNomics has entered into a research partnership with the Danish antibody company Genmab, the company announced today.
 
AlgoNomics plans to assist Genmab with detailed structural analysis of its fully human antibody molecules and antibody scaffolds, including Genmab’s new small, stable, modified antibody technology, UniBody.
 
Combined with experimental data, the companies believe structural information gleaned from AlgoNomics’ antibody structure database and structure-based protein and peptide design platform, Tripole, may reveal new functional or therapeutic properties for Genmab’s products.
 
AlgoNomics said that it will be eligible for Genmab research funding and milestone payments under the agreement, but did not disclose any other financial details or additional information about potential therapeutics.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.